SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participants
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.01238-24 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Lauren Rodriguez und 14 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences, Inc., Foster City, California, USA. Hauptthemen laut MEDLINE: Alanine, Adenosine Monophosphate, SARS-CoV-2, Antiviral Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences (Gilead).
Abstract (Originalsprache)
Remdesivir inhibits the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp; Nsp12). Here, we conducted viral resistance analyses from the Phase 3 PINETREE trial of remdesivir in nonhospitalized participants at risk of severe COVID-19. Nasopharyngeal swabs (collected at baseline [Day 1], Days 2, 3, 7, and 14) were eligible for analysis if their viral load was above the lower limit of quantification for the RT-qPCR assay (2228 copies/mL). The SARS-CoV-2 genome was sequenced for all remdesivir participants and 50% of placebo participants (baseline, Days 3, 7, and 14) and for participants who progressed to COVID-19-related hospitalization or all-cause death (all time points). Emergent substitutions in Nsp12 and other replication complex proteins were phenotyped using site-directed mutagenesis in a SARS-CoV-2 subgenomic replicon system. Overall, emergent Nsp12 substitutions were detected in 8/115 (7.0%) remdesivir participants and 7/129 (5.4%) placebo participants (1 substitution overlap between groups). Based on a structural analysis, none of the emergent Nsp12 substitutions were in direct contact with the incoming nucleoside triphosphate substrate, the RNA, or the RNA template 5′ overhang. One substitution (A376V) showed reduced susceptibility to remdesivir (12.6-fold change in remdesivir half-maximal concentration [EC 50 ]); it also showed reduced fitness when introduced in the SARS-CoV-2 replicon and virus in vitro . Other substitutions had
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gilead Sciences, Inc., Foster City, California, USA.
- Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada.
ORCID-Profile: Lauren Rodriguez
Förderung
- Gilead Sciences (Gilead)
Zitieren
APA
Rodriguez, L., Lee, H. W., Li, J., Martin, R., Han, D., Xu, S., Moshiri, J., Peinovich, N., Camus, G., Perry, J. K., Hyland, R. H., Porter, D. P., Abdelghany, M., Götte, M., & Hedskog, C. (2025). SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participants. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01238-24
Vancouver
Rodriguez L, Lee HW, Li J, Martin R, Han D, Xu S, et al. SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participants. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01238-24
BibTeX
@article{Rodriguez2025,
author = {Rodriguez, Lauren and Lee, Hery W and Li, Jiani and Martin, Ross and Han, Dong and Xu, Simin and Moshiri, Jasmine and Peinovich, Nadine and Camus, Gregory and Perry, Jason K and Hyland, Robert H and Porter, Danielle P and Abdelghany, Mazin and Götte, Matthias and Hedskog, Charlotte},
title = {SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participants},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.01238-24}
}
EUVIMED